GSK Annual Report 2008 199 Shareholder information Product development pipeline Key BLA Biological License Application In-license or other alliance relationship with third party MAA Marketing authorisation application Europe S Month of first submission NDA New drug application USA A Month of first regulatory approval for MAA, this is the first EU approval letter Phase I Evaluation of clinical pharmacology, usually conducted in volunteers Phase II Determination of dose and initial evaluation of efficacy, conducted in a AL Month Approvable or Complete Response Letter received indicates that ultimately approval can be given subject to resolution of small number of patients outstanding queries Phase III Large comparative study compound versus placebo and or established PO Month of EU Positive Opinion treatment in patients to establish clinical benefit and safety.
Estimated submission dates are only disclosed where they are within 12 months of the date of the chart.
This date represents the most likely year of submission where it is considered that there is a reasonably high probability of successfully meeting the date assuming the clinical data meets the expected end-points of the clinical trials.
Estimated submission dates Compound Type Indication Phase MAA NDA BLA Biopharmaceuticals 249320 monoclonal antibody stroke I 933776 monoclonal antibody Alzheimers disease I iboctadekin Doxil IL18 immunomodulator topoisomerase II ovarian cancer I inhibitor iboctadekin rituximab IL18 immunomodulator anti-CD20 non-Hodgkins lymphoma I monoclonal antibody 315234 monoclonal antibody rheumatoid arthritis II 679586 monoclonal antibody severe asthma II belimumab anti-B lymphocyte stimulator monoclonal systemic lupus erythematosus II antibody s. c. mepolizumab anti-IL5 monoclonal antibody severe asthma & nasal polyposis II ofatumumab anti-CD20 human monoclonal antibody diffuse large B cell lymphoma II ofatumumab anti-CD20 human monoclonal antibody multiple sclerosis II belimumab anti-B lymphocyte stimulator monoclonal systemic lupus erythematosus III antibody i. v. ofatumumab anti-CD20 human monoclonal antibody follicular lymphoma III ofatumumab anti-CD20 human monoclonal antibody rheumatoid arthritis III otelixizumab anti-CD3 monoclonal antibody type 1 diabetes III Syncria glucagon-like peptide 1 agonist type 2 diabetes III Bosatria mepolizumab anti-IL5 monoclonal antibody hypereosinophilic syndrome Submitted S:Sep08 ofatumumab anti-CD20 human monoclonal antibody refractory chronic lymphocytic leukaemia Submitted S:Feb09 S:Jan09 Cardiovascular & Metabolic 256073 high affinity nicotinic acid receptor HM74A dyslipidaemia I agonist 1278863 prolyl hydroxylase inhibitor anaemia I 1292263 gastrin-releasing peptide GRP receptor agonist type 2 diabetes I 1521498 mu-opioid receptor inverse agonist obesity I 1614235 sodium dependent glucose transport SGLT1 type 2 diabetes I inhibitor 2245840 SIRT1 activator type 2 diabetes also chronic obstructive pulmonary I disease, COPD 221149 oxytocin antagonist threatened pre-term labour II 756050 bile acid receptor agonist type 2 diabetes II 184072 SIRT1 activator type 2 diabetes also oncology indications II losmapimod 856553 p38 kinase inhibitor cardiovascular disease also COPD & depression II pazopanib multi-kinase angiogenesis inhibitor eye drops age-related macular degeneration also cancer indications II remogliflozin etabonate SGLT2 inhibitor type 1 diabetes II remogliflozin etabonate SGLT2 inhibitor type 2 diabetes II rilapladib Lp-PLA2 inhibitor atherosclerosis II ronacaleret calcium antagonist osteoporosis & fracture healing II Avandamet XR PPAR gamma agonist metformin type 2 diabetes extended release III N A Avandia simvastatin PPAR gamma agonist statin type 2 diabetes III N A darapladib Lp-PLA2 inhibitor atherosclerosis III Arixtra synthetic factor Xa inhibitor treatment of acute coronary syndrome Approved A:Aug07 AL:Feb07 & Sep07 Avandia PPAR gamma agonist prevention of disease progression Approved S:Nov08 A:Jul08 Volibris endothelin A antagonist pulmonary arterial hypertension Approved A:Apr08 N A 200 GSK Annual Report 2008 Shareholder information Product development pipeline continued Estimated submission dates Compound Type Indication Phase MAA NDA Infectious Diseases 932121 plasmodium electron transport chain inhibitor malaria I 945237 topoisomerase II inhibitor treatment of bacterial infections I 1265744 HIV integrase inhibitor HIV infections I 1322322 novel class antibacterial agent treatment of bacterial infections I 1349572 HIV integrase inhibitor HIV infections II IDX899 non-nucleotide reverse transcriptase inhibitor HIV infections II sitamaquine 8-aminoquinoline treatment of visceral leishmaniasis II N A tafenoquine 8-aminoquinoline Plasmodium vivax malaria II Neurosciences 163090 5HT1 antagonist depression & anxiety I 424887 NK1 antagonist SSRI depression & anxiety I 586529 CRF1 antagonist depression & anxiety I 598809 dopamine D3 antagonist drug dependency I 618334 dopamine D3 antagonist drug dependency I 729327 AMPA receptor modulator schizophrenia I 1014802 sodium channel blocker bipolar disorder I 1018921 type 1 glycine transport inhibitor schizophrenia I 1034702 muscarinic acetylcholine agonist dementia I 1144814 NK1 NK3 antagonist schizophrenia I 1482160 purinergic ATP receptor antagonist pain I orvepitant NK1 antagonist depression & anxiety I 239512 histamine H3 antagonist dementia II 468816 glycine antagonist smoking cessation II 561679 CRF1 antagonist depression & anxiety II 649868 orexin antagonist sleep disorders II 681323 p38 kinase inhibitor neuropathic pain II 742457 5HT6 antagonist dementia II firategrast dual alpha4 integrin antagonist VLA4 multiple sclerosis II losmapimod 856553 p38 kinase inhibitor depression also cardiovascular disease & COPD II Solzira 1838262 voltage-gated calcium channel modulator migraine prophylaxis II Solzira 1838262 voltage-gated calcium channel modulator neuropathic pain II almorexant orexin antagonist insomnia III Lamictal XR sodium channel inhibitor epilepsy partial generalised tonic-clonic seizures, once-daily III N A 2009 retigabine neuronal potassium channel opener epilepsy partial seizures III rosiglitazone XR PPAR gamma agonist Alzheimers disease III Lunivia non-benzodiazepine GABA agonist insomnia Submitted PO:Oct08 N A Solzira 1838262 voltage-gated calcium channel modulator restless legs syndrome Submitted S:Sep08 & Jan09 Lamictal XR sodium channel inhibitor epilepsy partial seizures, once-daily Approvable N A AL: Sep07 Requip Modutab XL non-ergot dopamine agonist Parkinsons disease once-daily controlled release formulation Approved A:Mar07 A:Jun08 Treximet 5HT1 agonist naproxen migraine fixed dose combination Approved N A A:Apr08 GSK Annual Report 2008 201 Shareholder information Product development pipeline continued Estimated submission dates Compound Type Indication Phase MAA NDA Oncology 461364 polo-like kinase inhibitor cancer I 923295  protein E CENP-E cancer I inhibitor 1120212 mitogen-activated protein kinase inhibitor cancer I MEK1 2 totrombopag thrombopoietin receptor agonist thrombocytopaenia I 184072 SIRT1 activator colon & haematologic cancers also type 2 diabetes II 1363089  transition factor papillary renal cell carcinoma, gastric cancer and II C-met kinase inhibitor head & neck squamous cell carcinoma pazopanib multi-kinase angiogenesis inhibitor non-small cell lung cancer II pazopanib multi-kinase angiogenesis inhibitor ovarian cancer II pazopanib multi-kinase angiogenesis inhibitor Her2 and metastatic breast cancer II Tyverb Tykerb epidermal growth factor receptor EGFR dual kinase inhibitor Revolade Promacta thrombopoietin receptor agonist oncology-related thrombocytopaenia II Tyverb Tykerb Her2 and EGFR dual kinase inhibitor head & neck squamous cell carcinoma unresectable disease II Tyverb Tykerb Her2 and EGFR dual kinase inhibitor refractory inflammatory breast cancer II Avodart 5-alpha reductase inhibitor reduction in the risk of prostate cancer III 2009 2009 elesclomol oxidative stress inducer metastatic melanoma III pazopanib multi-kinase angiogenesis inhibitor sarcoma III pazopanib multi-kinase angiogenesis inhibitor Her2 inflammatory breast cancer III Tyverb Tykerb and EGFR dual kinase inhibitor Revolade Promacta thrombopoietin receptor agonist chronic liver disease induced thrombocytopaenia III Revolade Promacta thrombopoietin receptor agonist hepatitis C induced thrombocytopaenia III Tyverb Tykerb Her2 and EGFR dual kinase inhibitor breast cancer, adjuvant therapy III Tyverb Tykerb Her2 and EGFR dual kinase inhibitor breast cancer, first line therapy III 2009 2009 Tyverb Tykerb Her2 and EGFR dual kinase inhibitor gastric cancer III Tyverb Tykerb Her2 and EGFR dual kinase inhibitor head & neck squamous cell carcinoma resectable disease III Duodart Avodart 5-alpha reductase inhibitor alpha blocker benign prostatic hyperplasia - fixed dose combination Submitted S:Dec08 2009 alpha blocker pazopanib multi-kinase angiogenesis inhibitor renal cell cancer also age-related macular degeneration Submitted S:Feb09 S:Dec08 Zunrisa Rezonic NK1 antagonist chemotherapy-induced & postoperative nausea & vomiting Submitted S:Jul08 S:May08 Hycamtin topoisomerase I inhibitor oral small cell lung cancer, second-line therapy Approved A:Mar08 A:Oct07 Revolade Promacta thrombopoietin receptor agonist idiopathic thrombocytopaenic purpura Approved S:Dec08 A:Nov08 Tyverb Tykerb Her2 and EGFR dual kinase inhibitor refractory breast cancer Approved A:Jun08 A:Mar07 Respiratory & Immuno-inflammation 610677 p38 kinase inhibitor inhaled COPD I 656933 Chemokine receptor CXCR2 antagonist cystic fibrosis & COPD I 705498 transient receptor potential vanilloid TRPV1 non-allergic rhinitis I antagonist intranasal 962040 motilin receptor agonist delayed gastric emptying I 1399686 anti-inflammatory macrolide conjugate oral inflammatory bowel disease I 2245840 SIRT1 activator COPD also type 2 diabetes I 159797 long-acting beta2 agonist COPD, also COPD & asthma in combination with a II glucocorticoid agonist 159802 long-acting beta2 agonist COPD, also COPD & asthma in combination with a II glucocorticoid agonist 256066 PDE IV inhibitor inhaled asthma & COPD II 573719 muscarinic acetylcholine antagonist COPD II 685698 glucocorticoid agonist asthma, also COPD & asthma in combination with a II long-acting beta2 agonist 835726 histamine H1 H3 dual antagonist oral allergic rhinitis II 870086 novel glucocorticoid agonist inhaled asthma II 642444 long-acting beta2 agonist COPD, also COPD & asthma in combination with a II glucocorticoid agonist 961081 muscarinic antagonist, beta2 agonist COPD II 1004723 histamine H1 H3 dual antagonist intranasal allergic rhinitis II 2190915  protein FLAP asthma II inhibitor darotropium muscarinic acetylcholine antagonist COPD II darotropium 642444 muscarinic acetylcholine antagonist COPD II long-acting beta2 agonist losmapimod 856553 p38 kinase inhibitor oral COPD also cardiovascular disease & depression II Entereg peripheral mu-opioid antagonist post operative ileus Approved N A A:May08 See Note 40 to the financial statements, Post balance sheet events.
202 GSK Annual Report 2008 Shareholder information Product development pipeline continued Estimated submission dates Compound Type Indication Phase MAA BLA Paediatric Vaccines Mosquirix recombinant malaria prophylaxis II Hib-MenCY-TT conjugated Neisseria meningitis groups C & Y disease & Haemophilus III 2009 influenzae type b disease prophylaxis MenACWY-TT conjugated Neisseria meningitis groups A, C, W & Y disease prophylaxis III Synflorix conjugated Streptococcus pneumoniae diseases prophylaxis in infants Submitted PO:Jan09 & children Kinrix subunit inactivated diphtheria, tetanus, pertussis and poliomyelitis prophylaxis Approved A:Jun08 booster 5th dose Rotarix live attenuated oral rotavirus-induced gastroenteritis prophylaxis Approved A:Feb06 A:Apr08 Other Vaccines Cytomegalovirus recombinant cytomegalovirus infection prophylaxis I HIV recombinant HIV infection prophylaxis I NTHi-Pneumo recombinant Streptococcus pneumoniae and Haemophilus influenzae I disease prophylaxis in adults S. pneumoniae adult recombinant conjugated Streptococcus pneumoniae disease prophylaxis I Tuberculosis recombinant tuberculosis prophylaxis II Zoster recombinant Herpes Zoster prevention II Flu pandemic & H5N1 inactivated split monovalent pandemic influenza prophylaxis III 2009 2009 pre-pandemic Quebec New generation flu vaccine inactivated split - trivalent seasonal influenza prophylaxis for the elderly III Simplirix recombinant genital herpes prophylaxis III Boostrix subunit adult booster for diphtheria, tetanus & pertussis Approved A:Jun00 A:Dec08 Pandemrix Flu pandemic H5N1 inactivated split monovalent pandemic influenza prophylaxis Approved A:May08 Dresden Prepandrix H5N1 inactivated split monovalent pre-pandemic influenza prophylaxis Approved A:May08 Flu pre-pandemic Dresden Cervarix recombinant human papilloma virus infection prophylaxis Approved A:Sep07 AL:Dec07 Antigen Specific Cancer Immunotherapeutic ASCI WT1 recombinant treatment of acute myelogenous leukaemia I MAGE-A3 ASCI recombinant treatment of melanoma III MAGE-A3 ASCI recombinant treatment of non-small cell lung cancer III
